|
| foundation = | location = Laval, Quebec, Canada〔 | key_people = | industry = Pharmaceutical industry | products = | revenue = (Q2 2015)〔 | operating_income = (Q2 2015) | net_income = (Q2 2015)〔 | assets = | equity = | num_employees = | subsid = Agouron Pharmaceuticals, G. D. Searle & Company, Innopharma, Greenstone, Parke-Davis, Pfizer UK, Warner Lambert, Wyeth, Zoetis | homepage = |subsid = }} Valeant Pharmaceuticals International, Inc. is a publicly traded multinational specialty drugs company based in Laval, Quebec, Canada. The company focuses on purchasing the rights to older generic drugs and raising prices, sometimes to hundreds or thousands of dollars per pill.〔http://www.nytimes.com/2015/10/05/business/valeants-drug-price-strategy-enriches-it-but-infuriates-patients-and-lawmakers.html〕 Valeant's main drug markets include neurology, dermatology and infectious disease with several drugs in late-stage clinical trials and several currently on the market. In addition, Valeant has a portfolio of more than 500 products from its prior history as a group of specialty chemical and radiochemical research, development and supply companies with a history stretching back to the 1960s. Valeant's strategy of exponential price increases on lifesaving medicines has been described by Berkshire Hathaway Vice Chariman Charlie Munger as "deeply immoral" and "similar to the worst abuses in for-profit education."〔http://www.bloomberg.com/news/articles/2015-11-01/munger-isn-t-done-bashing-valeant-after-months-of-holding-nose〕 Valeant sells a wide range of drugs, including over-the counter medications and medical devices, as well as prescription drugs such as antidepressant Wellbutrin XL.〔 Kinerase, which uses kinetin as active ingredient, is one of the most popular products of Valeant. An important part of the growth strategy for Valeant has been acquisitions, sometimes in the multibillion-dollar range, of medical and pharmaceutical companies.〔 As of July 2015, the company was valued at over $90 billion USD ($116 billion CAD) by market capitalization, making it the largest public company in Canada and the largest pharmaceutical company in the nation.〔 By October 2015 Valeant's stock price had dropped to just less than $72.60 USD (approximately $126 CAD), giving a market capitalisation of $24.77 billion USD ($43 billion CAD). This represents a decrease of approximately 80% since the July high. ==Corporate history, mergers and acquisitions== Valeant was founded as a United States business.〔 In the 1990s shareholders of several group units approved the merger of ICN Pharmaceuticals (founded by Milan Panić), ICN Biomedicals, SPI Pharmaceuticals and Viratek into a new global entity, ICN Pharmaceuticals, the immediate forebear of Valeant. Since then, the company has undergone major management, operational and strategic restructurings during the tenure of Pearson as intermim president and then CEO from 2007. Valeant Pharmaceuticals is considered to be the poster-company for a new lucrative business model for pharmaceutical companies with its high-profile takeovers.〔 Since 1995 using this model, smaller pharmaceutical companies refocused away from research and development towards serial acquisitions of existing technologies, more aggressive marketing and rapid price increases to enhance growth. Valeant's highly lucrative〔〔〔 business model instituted in 2008 which won both the CEO and the company a number of awards, earned negative media attention by September 2015.〔〔〔〔 The value of stocks rose exponentially but also attracted negative attention of regulators in the United States〔 particularly after the publication in the New York Times of an article by Andrew Pollack on price gouging of specialty drugs. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Valeant Pharmaceuticals」の詳細全文を読む スポンサード リンク
|